Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects.
Bottom Line: In addition, ASKP1240 did not destabilize platelet thrombi under physiological high shear conditions while mouse anti-human CD154 mAb (mu5C8) did.And ASKP1240 itself did not activate platelet and endothelial cells.The immunosuppressive effect was well correlated with the CD40 receptor saturation.
Affiliation: Development Research Laboratories, Kyowa Hakko Kirin Co., Ltd., Shizuoka, Japan.Show MeSH
Related in: MedlinePlus
Mentions: The ASKP1240 inhibited DTH reaction in a dose-dependent manner (Figure 4A). Histopathologically, vasculitis and inflammatory cell infiltration including mononuclear cells and acidophils were observed in the dermis and subcutis at the challenge sites injected with TTx in the control group, but not at the sites injected with physiological saline. The incidences and degrees of histological changes decreased dose dependently (data not shown). Anti-TTx antibodies were also assessed over time, through day 23. ASKP1240 dose-dependently inhibited anti-TTx IgG and anti-TTx IgM productions (Figure 4B and C) with complete inhibition in antibody formation seen at doses of 10 mg/kg.
Affiliation: Development Research Laboratories, Kyowa Hakko Kirin Co., Ltd., Shizuoka, Japan.